Shattuck Labs (NASDAQ:STTK) Reaches New 12-Month High at $11.19

Shattuck Labs, Inc. (NASDAQ:STTK) hit a new 52-week high during trading on Monday . The company traded as high as $11.19 and last traded at $11.19, with a volume of 449 shares traded. The stock had previously closed at $10.59.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on STTK. Needham & Company LLC reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Shattuck Labs in a research note on Tuesday, April 9th. HC Wainwright reaffirmed a “buy” rating and issued a $28.00 price objective on shares of Shattuck Labs in a research note on Friday, March 1st.

Shattuck Labs Price Performance

The firm has a 50 day moving average of $9.25 and a two-hundred day moving average of $6.70.

Shattuck Labs (NASDAQ:STTK) last announced its quarterly earnings results on Thursday, February 29th. The company reported ($0.41) EPS for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.10. Shattuck Labs had a negative return on equity of 63.08% and a negative net margin of 5,268.44%. The firm had revenue of $0.71 million for the quarter, compared to analyst estimates of $0.50 million. Equities analysts predict that Shattuck Labs, Inc. will post -1.85 EPS for the current fiscal year.

Insider Activity

In other news, insider Stephen Stout sold 16,004 shares of Shattuck Labs stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $10.53, for a total transaction of $168,522.12. Following the sale, the insider now directly owns 74,437 shares of the company’s stock, valued at $783,821.61. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 9.46% of the company’s stock.

Institutional Trading of Shattuck Labs

A number of hedge funds have recently made changes to their positions in STTK. Cannon Global Investment Management LLC bought a new stake in Shattuck Labs in the first quarter valued at approximately $91,000. Tower Research Capital LLC TRC lifted its position in shares of Shattuck Labs by 79.2% in the 4th quarter. Tower Research Capital LLC TRC now owns 13,553 shares of the company’s stock worth $97,000 after purchasing an additional 5,989 shares during the period. Reliant Investment Management LLC bought a new stake in shares of Shattuck Labs in the 4th quarter valued at $143,000. SG Americas Securities LLC bought a new stake in shares of Shattuck Labs in the 4th quarter valued at $268,000. Finally, Monashee Investment Management LLC bought a new stake in shares of Shattuck Labs in the 4th quarter valued at $713,000. 58.74% of the stock is owned by institutional investors and hedge funds.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.